GlaxoSmithKline and Dynavax form alliance
Under the terms of the alliance, Dynavax will receive an initial payment of $10 million for which GlaxoSmithKline (GSK) will receive an exclusive option over four programs targeting
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).